278 related articles for article (PubMed ID: 22923450)
21. Roles of p300 and cyclic adenosine monophosphate response element binding protein in high glucose-induced hypoxia-inducible factor 1α inactivation under hypoxic conditions.
Ding L; Yang M; Zhao T; Lv G
J Diabetes Investig; 2017 May; 8(3):277-285. PubMed ID: 27808477
[TBL] [Abstract][Full Text] [Related]
22. A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain.
Wu D; Zhang R; Zhao R; Chen G; Cai Y; Jin J
PLoS One; 2013; 8(5):e62014. PubMed ID: 23671581
[TBL] [Abstract][Full Text] [Related]
23. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
[TBL] [Abstract][Full Text] [Related]
24. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.
Jensen RL; Ragel BT; Whang K; Gillespie D
J Neurooncol; 2006 Jul; 78(3):233-47. PubMed ID: 16612574
[TBL] [Abstract][Full Text] [Related]
26. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
27. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.
Ellinghaus P; Heisler I; Unterschemmann K; Haerter M; Beck H; Greschat S; Ehrmann A; Summer H; Flamme I; Oehme F; Thierauch K; Michels M; Hess-Stumpp H; Ziegelbauer K
Cancer Med; 2013 Oct; 2(5):611-24. PubMed ID: 24403227
[TBL] [Abstract][Full Text] [Related]
28. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Birle DC; Hedley DW
Cancer Res; 2007 Feb; 67(4):1735-43. PubMed ID: 17308115
[TBL] [Abstract][Full Text] [Related]
29. NF-κB suppresses HIF-1α response by competing for P300 binding.
Mendonça DB; Mendonça G; Aragão FJ; Cooper LF
Biochem Biophys Res Commun; 2011 Jan; 404(4):997-1003. PubMed ID: 21187066
[TBL] [Abstract][Full Text] [Related]
30. Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α.
Ma J; Zi Jiang Y; Shi H; Mi C; Li J; Xing Nan J; Wu X; Joon Lee J; Jin X
Eur J Pharmacol; 2014 Jan; 723():46-54. PubMed ID: 24333213
[TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α.
Nepal M; Choi HJ; Choi BY; Kim SL; Ryu JH; Kim DH; Lee YH; Soh Y
Eur J Pharmacol; 2012 Sep; 691(1-3):28-37. PubMed ID: 22760073
[TBL] [Abstract][Full Text] [Related]
32. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
33. Complex regulation of the transactivation function of hypoxia-inducible factor-1 alpha by direct interaction with two distinct domains of the CREB-binding protein/p300.
Ruas JL; Berchner-Pfannschmidt U; Malik S; Gradin K; Fandrey J; Roeder RG; Pereira T; Poellinger L
J Biol Chem; 2010 Jan; 285(4):2601-9. PubMed ID: 19880525
[TBL] [Abstract][Full Text] [Related]
34. An allosteric peptide inhibitor of HIF-1α regulates hypoxia-induced retinal neovascularization.
Usui-Ouchi A; Aguilar E; Murinello S; Prins M; Gantner ML; Wright PE; Berlow RB; Friedlander M
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28297-28306. PubMed ID: 33106407
[TBL] [Abstract][Full Text] [Related]
35. Hypoxic adaptation engages the CBP/CREST-induced coactivator complex of Creb-HIF-1α in transactivating murine neuroblastic glucose transporter.
Thamotharan S; Raychaudhuri N; Tomi M; Shin BC; Devaskar SU
Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E583-98. PubMed ID: 23321477
[TBL] [Abstract][Full Text] [Related]
36. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
37. HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.
Kessler J; Hahnel A; Wichmann H; Rot S; Kappler M; Bache M; Vordermark D
BMC Cancer; 2010 Nov; 10():605. PubMed ID: 21050481
[TBL] [Abstract][Full Text] [Related]
38. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Rapisarda A; Uranchimeg B; Scudiero DA; Selby M; Sausville EA; Shoemaker RH; Melillo G
Cancer Res; 2002 Aug; 62(15):4316-24. PubMed ID: 12154035
[TBL] [Abstract][Full Text] [Related]
39. Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound.
Park K; Lee HE; Lee SH; Lee D; Lee T; Lee YM
Oncotarget; 2017 Jan; 8(5):7801-7813. PubMed ID: 27999195
[TBL] [Abstract][Full Text] [Related]
40. Insights from molecular dynamics simulations and steered molecular dynamics simulations to exploit new trends of the interaction between HIF-1α and p300.
Yu Z; Liu Y; Zhu J; Han J; Tian X; Han W; Zhao L
J Biomol Struct Dyn; 2020 Jan; 38(1):1-12. PubMed ID: 30784357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
